Shree Ganesh Remedies Limited announced its unaudited financial results for Q2FY27 and H1FY27 ended September 30, 2026. The company reported significant year-over-year declines across key financial metrics but showed quarter-over-quarter improvement from a weak Q1 performance.

Financial Performance Highlights

Q2FY27 Performance (₹ in crores):

  • Revenue from Operations: ₹23.29 crore (down 23% YoY from ₹30.32 crore in Q2FY26, but up 62% QoQ from ₹14.36 crore in Q1FY27)
  • Total Income: ₹24.70 crore (down 20% YoY, up 61% QoQ)
  • Operating Expenses: ₹19.36 crore (down 6% YoY, up 76% QoQ)
  • EBITDA (Excluding OI & EI): ₹3.94 crore (down 59% YoY, up 17% QoQ)
  • EBITDA Margin: 16.9% (down 1,483 basis points YoY, down 644 basis points QoQ)
  • Finance Cost: ₹0.58 crore (down 43% YoY, up 80% QoQ)
  • Depreciation & Amortization: ₹2.50 crore (down 3% YoY, up 3% QoQ)
  • PBT: ₹2.26 crore (down 66% YoY, up 48% QoQ)
  • PAT: ₹1.63 crore (down 67% YoY, up 46% QoQ)
  • EPS: ₹1.28 (down 67% YoY, up 47% QoQ)

H1FY27 Performance (₹ in crores):

  • Revenue from Operations: ₹37.65 crore (down 32% YoY from ₹54.98 crore in H1FY26)
  • Total Income: ₹40.00 crore (down 29% YoY)
  • Operating Expenses: ₹30.37 crore (down 20% YoY)
  • EBITDA (Excluding OI & EI): ₹7.29 crore (down 57% YoY)
  • EBITDA Margin: 19.4% (down 1,141 basis points YoY)
  • Finance Cost: ₹0.89 crore (down 54% YoY)
  • Depreciation & Amortization: ₹4.94 crore (down 1% YoY)
  • PBT: ₹3.79 crore (down 66% YoY)
  • PAT: ₹2.75 crore (down 67% YoY)
  • EPS: ₹2.15 (down 67% YoY)

Business Segment Performance

  • Revenue from Pharma Intermediates in H1FY27: ₹25.10 crore
  • Revenue from Specialty Chemicals in H1FY27: ₹12.25 crore
  • Revenue from Exports in H1FY27: ₹20.35 crore
  • Revenue from Domestic Sales in H1FY27: ₹17.00 crore

Management Commentary

Promoter Mr. Gunjan Kothia stated that FY27 began on a challenging note due to subdued demand from Europe and difficult operating environment. The company sharpened focus on domestic market to compensate for softer exports. European customer traction has shown improvement, providing confidence for core business recovery over next few quarters.

Product Development and Expansion

  • Commenced commercial production of two new pharmaceutical intermediates for anti-diabetic and cardiovascular applications
  • Both new products received encouraging response in domestic market, with plans to introduce to export markets in coming quarters
  • Specialty chemicals project for South-East Asian markets completed pilot trials, with batches undergoing stability testing
  • Commercial supplies of specialty chemicals expected from Q1FY28
  • Second specialty chemicals product for same region cleared laboratory trials and moved to pilot stage
  • Progress on two molecules for pharmaceutical and agrochemical applications in Europe
  • Construction of Block 7A completed with trials begun

Outlook

Management expects input costs to ease as geopolitical conditions stabilize and margins to normalize as sales return to earlier levels. The company remains focused on healthy profitability including on new products. With core business recovering, new products gaining traction and new capacity coming online, the company looks forward to stronger performance in periods ahead.